Formulation
+
ABOUT US
Founded in 2000, Suzhou Tianji Biopharma is the flagship company of Suzhou Tianma Pharma Group and a national High-Tech Enterprise, home to a provincial-level Enterprise Technology Center in Jiangsu. With more than two decades focused on peptide pharmaceuticals, we bring R&D, manufacturing, sales, and technical services together under one roof. We operate across the full peptide and small-molecule value chain — peptide and small-molecule APIs, lyophilized powder injections, small-volume injectables, and topical formulations — complemented by custom peptide development and integrated CRO, CMO, and CDMO services, with complete in-house capabilities from synthesis, purification, and formulation development through regulatory filing and commercial-scale manufacturing. Our products span immunomodulation, women’s health, gastroenterology, pain management, oncology, and metabolic disease, with several having completed China’s generic drug consistency Evaluation. Our peptide APIs — including advanced classes such as GLP-1 and oral cyclic peptides — supply both domestic and international markets, with select products approved by overseas regulators. We are also steadily advancing a proprietary pipeline of improved (505(b)(2)-type) new drugs. Guided by strict GMP quality management and an ongoing commitment to innovation and quality, Tianji Biopharma remains dedicated to peptides — delivering reliable products and expert technical solutions to pharmaceutical partners worldwide.
PRODUCT
R & D
NEWS
